Efficacy of a Micronized, Nanocrystal Fenofibrate Formulation in Treatment of Hyperlipidemia in Dogs

Overview

Journal J Vet Intern Med

Specialties General Medicine
Veterinary Medicine

Date 2021 Jun 7

PMID 34096101

Citations 2

Authors

Matthew J L Munro

Sean E Hulsebosch

Stanley L Marks

Chen Gilor

Affiliations

Soon will be listed here.

Abstract

Background: Safe, effective, and readily available drug therapies are required for the management of hyperlipidemia and its associated complications in dogs.

Objectives: To investigate the efficacy of a micronized, nanocrystal formulation of fenofibrate (Tricor) in the treatment of hyperlipidemia in dogs.

Animals: Ten client-owned dogs with primary (n = 7) and secondary (n = 3) hyperlipidemia. All dogs had hypertriglyceridemia at baseline; 3 dogs also had hypercholesterolemia.

Methods: Prospective dose-escalation study. Dogs were treated with fenofibrate orally once daily in up to 3 cycles of 21 days each. Fenofibrate dose was increased at the end of each cycle if hypertriglyceridemia persisted and adverse effects were not documented. Complete blood count, biochemistry, and urine protein:creatinine ratio were collected serially. Baseline (T0) parameters were compared to time of maximal reduction in serum triglyceride concentrations (T1) and reported as median (range).

Results: Triglycerides normalized in all dogs (T0 = 662 mg/dL [189-2391]; T1 = 113 mg/dL [81-132]; P = .002). Fenofibrate dose at T1 = 6.4 mg/kg PO q24h (range, 2.2-13.5). T1 was achieved at 3 (n = 4), 6 (n = 4), and 9 (n = 2) weeks. Serum cholesterol concentrations decreased in 9 of 10 dogs. Quiet demeanor and firm stools in 1 dog were the only reported adverse reactions. Fenofibrate administration resulted in a significant reduction in median alkaline phosphatase activity (P = .049).

Conclusions And Clinical Importance: Over 21 to 63 days, TriCor was effective in the management of primary and secondary hyperlipidemia in dogs.

Citing Articles

Sustained-Release Solid Dispersions of Fenofibrate for Simultaneous Enhancement of the Extent and Duration of Drug Exposure.

Park S, Kim G, Han H Pharmaceutics. 2025; 16(12.

PMID: 39771594 PMC: 11676638. DOI: 10.3390/pharmaceutics16121617.

Therapy for feline secondary hypertriglyceridemia with fenofibrate.

Miceli D, Guevara J, Ferraris S, Pignataro O, Gallelli M J Feline Med Surg. 2022; 24(8):e251-e257.

PMID: 35713593 PMC: 10812274. DOI: 10.1177/1098612X221104066.

Efficacy of a micronized, nanocrystal fenofibrate formulation in treatment of hyperlipidemia in dogs.

Munro M, Hulsebosch S, Marks S, Gilor C J Vet Intern Med. 2021; 35(4):1733-1742.

PMID: 34096101 PMC: 8295657. DOI: 10.1111/jvim.16190.

References

Hess R, Kass P, Shofer F, Van Winkle T, Washabau R . Evaluation of risk factors for fatal acute pancreatitis in dogs. J Am Vet Med Assoc. 1999; 214(1):46-51. View

Shropshire S, Quimby J, Cerda R . Comparison of Single, Averaged, and Pooled Urine Protein:Creatinine Ratios in Proteinuric Dogs Undergoing Medical Treatment. J Vet Intern Med. 2017; 32(1):288-294. PMC: 5787151. DOI: 10.1111/jvim.14872. View

Jeong S, Han M, Lee H, Kim M, Kim J, Nicol C . Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice. Metabolism. 2004; 53(10):1284-9. DOI: 10.1016/j.metabol.2004.05.003. View

Hottelart C, El Esper N, Rose F, Achard J, Fournier A . Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002; 92(3):536-41. DOI: 10.1159/000064083. View

Miceli D, Vidal V, Blatter M, Pignataro O, Castillo V . Fenofibrate treatment for severe hypertriglyceridemia in dogs. Domest Anim Endocrinol. 2020; 74:106578. DOI: 10.1016/j.domaniend.2020.106578. View

Sando K, Knight M . Nonstatin therapies for management of dyslipidemia: a review. Clin Ther. 2015; 37(10):2153-79. DOI: 10.1016/j.clinthera.2015.09.001. View

Hess R, Kass P, Van Winkle T . Association between diabetes mellitus, hypothyroidism or hyperadrenocorticism, and atherosclerosis in dogs. J Vet Intern Med. 2003; 17(4):489-94. DOI: 10.1111/j.1939-1676.2003.tb02469.x. View

Nabity M, Boggess M, Kashtan C, Lees G . Day-to-Day variation of the urine protein: creatinine ratio in female dogs with stable glomerular proteinuria caused by X-linked hereditary nephropathy. J Vet Intern Med. 2007; 21(3):425-30. DOI: 10.1892/0891-6640(2007)21[425:dvotup]2.0.co;2. View

Farnier M . Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. Vasc Health Risk Manag. 2009; 4(5):991-1000. PMC: 2605343. DOI: 10.2147/vhrm.s3390. View

10.

Kohnken R, Amerman H, Brown C, Furrow E, Lees G, Cianciolo R . Glomerular Lipidosis in Dogs. Vet Pathol. 2017; 54(5):795-801. PMC: 5784413. DOI: 10.1177/0300985817709889. View

11.

Sauron R, Wilkins M, Jessent V, Dubois A, Maillot C, Weil A . Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation. Int J Clin Pharmacol Ther. 2006; 44(2):64-70. DOI: 10.5414/cpp44064. View

12.

Xenoulis P, Cammarata P, Walzem R, Suchodolski J, Steiner J . Effect of a low-fat diet on serum triglyceride and cholesterol concentrations and lipoprotein profiles in Miniature Schnauzers with hypertriglyceridemia. J Vet Intern Med. 2020; 34(6):2605-2616. PMC: 7694839. DOI: 10.1111/jvim.15880. View

13.

Cook A, Cowgill L . Clinical and pathological features of protein-losing glomerular disease in the dog: a review of 137 cases (1985-1992). J Am Anim Hosp Assoc. 1996; 32(4):313-22. DOI: 10.5326/15473317-32-4-313. View

14.

Mori N, Lee P, Muranaka S, Sagara F, Takemitsu H, Nishiyama Y . Predisposition for primary hyperlipidemia in Miniature Schnauzers and Shetland sheepdogs as compared to other canine breeds. Res Vet Sci. 2010; 88(3):394-9. DOI: 10.1016/j.rvsc.2009.12.003. View

15.

Serisier S, Briand F, Ouguerram K, Siliart B, Magot T, Nguyen P . Fenofibrate lowers lipid parameters in obese dogs. J Nutr. 2006; 136(7 Suppl):2037S-2040S. DOI: 10.1093/jn/136.7.2037S. View

16.

Adkins J, Faulds D . Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs. 1997; 54(4):615-33. DOI: 10.2165/00003495-199754040-00007. View

17.

Danielsson B, Ekman R, Johansson B, Petersson B . Plasma lipoprotein changes in experimental cholestasis in the dog. Clin Chim Acta. 1977; 80(1):157-70. DOI: 10.1016/0009-8981(77)90275-3. View

18.

Aguirre A, Center S, Randolph J, Yeager A, Keegan A, Harvey H . Gallbladder disease in Shetland Sheepdogs: 38 cases (1995-2005). J Am Vet Med Assoc. 2007; 231(1):79-88. DOI: 10.2460/javma.231.1.79. View

19.

Xenoulis P, Steiner J . Lipid metabolism and hyperlipidemia in dogs. Vet J. 2009; 183(1):12-21. DOI: 10.1016/j.tvjl.2008.10.011. View

20.

Smith R, Granick J, Stauthammer C, Polzin D, Heinrich D, Furrow E . Clinical Consequences of Hypertriglyceridemia-Associated Proteinuria in Miniature Schnauzers. J Vet Intern Med. 2017; 31(6):1740-1748. PMC: 5697203. DOI: 10.1111/jvim.14833. View